Skip to main content.

Research

Picture of Francie Diep
If you were to seek opioid addiction treatment for yourself or a loved one, what are the chances you'd run into a facility that didn’t offer the best possible treatment?
Picture of William Heisel
The zeal with which we turn to childhood adversity as a root cause of so many things borders on the religious, argues contributor Bill Heisel.
Picture of Priska Neely
Black babies in the U.S. are twice as likely to die as white babies in their first year. When I heard this decades-old statistic for the first time, it me like a slap to the face.
Picture of William Heisel
Instead of leaping onto the fearwagon when a bug seems to appear out of nowhere, check the science. Then consider seeking out the real infection hotspots in your community.
Picture of William Heisel
The trade in human body parts in still rife with problems, 17 years after the Orange County Register detailed the horrors in "The Body Brokers" series. A new Reuters investigation provides a gruesome update.
Picture of Tiffany Lankes
Buffalo News reporter Tiffany Lankes shows how data can create a story framework that comes alive with personal experiences to help readers understand the importance of addressing violence.
Picture of Earle Holland
An over-the-top University of Iowa news release about the ability of herb compounds to "cure" disease proves itself to be another a case study on how not to promote university research.
Picture of Jamie Hopkins
Hopkins reported this story with the support of the Dennis A. Hunt Fund for Health Journalism and the National Fellowship, programs of the University of Southern California Center for Health Journalism. Other stories in the series include: America’s super polluters The invisible hazard afflicting th
Picture of Maggie Clark

What to do when you can't find the right research for your story? A Florida newspaper pursued a novel collaboration with researchers on a new study on how the state's Medicaid program impacts children.

Picture of Rebecca Plevin

When extremely expensive new hepatitis C medications arrived on the market more than two years ago, private health insurers limited access to the very sickest. Now, two new analyses say that approach is shortsighted and counterproductive.

Pages

CONNECT WITH THE COMMUNITY

Follow Us

Facebook


Twitter

CHJ Icon
ReportingHealth